Victory Capital Management Inc. Acquires 124,727 Shares of MiMedx Group, Inc. (NASDAQ:MDXG)

Victory Capital Management Inc. raised its stake in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 909.0% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 138,449 shares of the company’s stock after purchasing an additional 124,727 shares during the period. Victory Capital Management Inc. owned 0.09% of MiMedx Group worth $959,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of MDXG. ProShare Advisors LLC increased its stake in shares of MiMedx Group by 8.5% in the first quarter. ProShare Advisors LLC now owns 20,735 shares of the company’s stock valued at $160,000 after buying an additional 1,631 shares during the period. Headlands Technologies LLC acquired a new stake in MiMedx Group during the 1st quarter valued at approximately $27,000. Price T Rowe Associates Inc. MD raised its holdings in MiMedx Group by 13.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 32,978 shares of the company’s stock worth $254,000 after purchasing an additional 3,806 shares during the last quarter. Entropy Technologies LP acquired a new position in shares of MiMedx Group in the 1st quarter worth approximately $99,000. Finally, Shell Asset Management Co. acquired a new position in shares of MiMedx Group in the 1st quarter worth approximately $113,000. 79.15% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on MDXG shares. Craig Hallum lowered their target price on shares of MiMedx Group from $14.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday, August 1st. StockNews.com upgraded MiMedx Group from a “buy” rating to a “strong-buy” rating in a report on Wednesday, September 4th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $11.00 price objective on shares of MiMedx Group in a research note on Thursday, August 1st. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $12.00.

MiMedx Group Trading Down 1.6 %

NASDAQ MDXG opened at $6.13 on Friday. MiMedx Group, Inc. has a 52 week low of $5.57 and a 52 week high of $9.27. The business has a 50 day moving average price of $6.67 and a 200-day moving average price of $7.02. The company has a quick ratio of 3.22, a current ratio of 3.85 and a debt-to-equity ratio of 0.11. The company has a market cap of $904.81 million, a price-to-earnings ratio of 13.93 and a beta of 1.98.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings data on Wednesday, July 31st. The company reported $0.08 earnings per share for the quarter, hitting the consensus estimate of $0.08. MiMedx Group had a net margin of 23.63% and a return on equity of 34.24%. The firm had revenue of $87.21 million for the quarter, compared to the consensus estimate of $88.44 million. As a group, equities analysts expect that MiMedx Group, Inc. will post 0.26 earnings per share for the current fiscal year.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.